State Street Corp Grows Stock Holdings in Zura Bio Limited (NASDAQ:ZURA)

State Street Corp raised its stake in Zura Bio Limited (NASDAQ:ZURA) by 47.5% in the third quarter, HoldingsChannel reports. The institutional investor owned 395,059 shares of the company’s stock after buying an additional 127,300 shares during the quarter. State Street Corp’s holdings in Zura Bio were worth $1,604,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of ZURA. Bank of New York Mellon Corp increased its stake in Zura Bio by 15.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock valued at $165,000 after purchasing an additional 6,412 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Zura Bio by 51.3% in the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock valued at $61,000 after purchasing an additional 5,900 shares during the period. Great Point Partners LLC lifted its holdings in shares of Zura Bio by 68.3% during the 2nd quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock worth $16,248,000 after acquiring an additional 1,884,501 shares during the period. Armistice Capital LLC boosted its holdings in Zura Bio by 53.2% in the second quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock valued at $8,834,000 after acquiring an additional 876,000 shares during the last quarter. Finally, AQR Capital Management LLC purchased a new stake in shares of Zura Bio during the 2nd quarter worth about $43,000. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Insider Activity

In related news, Director Parvinder Thiara sold 1,001,633 shares of the firm’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $2.73, for a total transaction of $2,734,458.09. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 22.10% of the stock is owned by insiders.

Zura Bio Price Performance

Shares of ZURA opened at $2.50 on Thursday. The stock’s fifty day moving average is $3.24 and its 200-day moving average is $3.61. Zura Bio Limited has a one year low of $2.00 and a one year high of $6.35.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Research analysts anticipate that Zura Bio Limited will post -0.65 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Chardan Capital decreased their target price on Zura Bio from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, November 8th. Leerink Partners started coverage on Zura Bio in a research report on Monday, November 4th. They set an “outperform” rating and a $15.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Zura Bio in a research report on Wednesday, December 11th. Piper Sandler restated an “overweight” rating and set a $26.00 price objective on shares of Zura Bio in a research note on Thursday, September 19th. Finally, Leerink Partnrs raised shares of Zura Bio to a “strong-buy” rating in a research report on Monday, November 4th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Zura Bio currently has an average rating of “Buy” and a consensus price target of $15.80.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.